| Date | Time | Source | Headline | Symbol | Company |
| 05/02/2024 | 10:07AM | InvestorsHub NewsWire | NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon | AMEX:NNVC | NanoViricides Inc |
| 02/16/2024 | 4:53PM | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NNVC | NanoViricides Inc |
| 02/14/2024 | 4:55PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | AMEX:NNVC | NanoViricides Inc |
| 01/19/2024 | 4:44PM | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NNVC | NanoViricides Inc |
| 12/04/2023 | 4:08PM | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | AMEX:NNVC | NanoViricides Inc |
| 10/13/2023 | 4:30PM | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | AMEX:NNVC | NanoViricides Inc |
| 09/28/2023 | 4:44PM | Edgar (US Regulatory) | Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | AMEX:NNVC | NanoViricides Inc |
| 09/01/2023 | 4:46PM | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NNVC | NanoViricides Inc |
| 07/06/2023 | 11:16AM | InvestorsHub NewsWire | Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs | AMEX:NNVC | NanoViricides Inc |
| 05/25/2023 | 4:34PM | Edgar (US Regulatory) | Current Report Filing (8-k) | AMEX:NNVC | NanoViricides Inc |
| 05/08/2023 | 5:20PM | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3/a) | AMEX:NNVC | NanoViricides Inc |
| 05/04/2023 | 6:45AM | GlobeNewswire Inc. | NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City | AMEX:NNVC | NanoViricides Inc |
| 02/14/2023 | 5:24PM | Edgar (US Regulatory) | Quarterly Report (10-q) | AMEX:NNVC | NanoViricides Inc |
| 02/13/2023 | 5:02PM | Edgar (US Regulatory) | Current Report Filing (8-k) | AMEX:NNVC | NanoViricides Inc |
| 12/23/2022 | 6:04AM | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | AMEX:NNVC | NanoViricides Inc |
| 11/15/2022 | 4:32PM | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | AMEX:NNVC | NanoViricides Inc |
| 11/04/2022 | 4:33PM | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) | AMEX:NNVC | NanoViricides Inc |
| 10/13/2022 | 5:13PM | Edgar (US Regulatory) | Annual Report (10-k) | AMEX:NNVC | NanoViricides Inc |
| 09/29/2022 | 12:20PM | Edgar (US Regulatory) | Notification That Annual Report Will Be Submitted Late (nt 10-k) | AMEX:NNVC | NanoViricides Inc |
| 08/10/2022 | 6:52PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | AMEX:NNVC | NanoViricides Inc |
| 05/16/2022 | 4:55PM | Edgar (US Regulatory) | Quarterly Report (10-q) | AMEX:NNVC | NanoViricides Inc |
| 11/15/2021 | 4:55PM | Edgar (US Regulatory) | Quarterly Report (10-q) | AMEX:NNVC | NanoViricides Inc |
| 11/15/2021 | 7:09AM | InvestorsHub NewsWire | NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2 | AMEX:NNVC | NanoViricides Inc |
| 10/12/2021 | 6:16AM | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | AMEX:NNVC | NanoViricides Inc |
| 10/11/2021 | 6:49AM | InvestorsHub NewsWire | NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity | AMEX:NNVC | NanoViricides Inc |
| 10/05/2021 | 6:45AM | PR Newswire (US) | NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference | AMEX:NNVC | NanoViricides Inc |
| 10/05/2021 | 6:45AM | PR Newswire (US) | NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference | AMEX:NNVC | NanoViricides Inc |
| 09/28/2021 | 4:32PM | Edgar (US Regulatory) | Notification That Annual Report Will Be Submitted Late (nt 10-k) | AMEX:NNVC | NanoViricides Inc |
| 09/22/2021 | 6:48AM | InvestorsHub NewsWire | Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug | AMEX:NNVC | NanoViricides Inc |
| 09/22/2021 | 6:45AM | PR Newswire (US) | Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug | AMEX:NNVC | NanoViricides Inc |